Gautret. P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M. and Doudier, B., et al. (2020) Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. The International Journal of Antimicrobial Agents, 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

has been cited by the following article:

• TITLE: Targeting Three-Dimensional Genome Architecture Might Be One of the Mechanisms of Chloroquine’s Diverse Therapeutic Actions

  AUTHORS: Gao-De Li

  KEYWORDS: Chloroquine, Hydroxychloroquine, Anticancer, Antivirus, SARS-CoV-2, Coronavirus Disease 2019 (COVID-19), Immunomodulatory Effects, Three-Dimensional Genome Architecture, Plasmodium falciparum Chloroquine-Resistance Marker Protein (Pfcrmp), Genome Architectural Protein

  JOURNAL NAME: Open Access Library Journal, Vol.7 No.5, May 15, 2020

  ABSTRACT: Chloroquine (CQ) was initially synthesized as an antimalarial agent, but later on, it also shows immunomodulatory, anticancer, and antiviral effects in clinical practice. Although CQ has been used to treat various conditions for more than half century, the underlying mechanisms of its diverse therapeutic actions remain incomplete. In this paper, we hypothesize that targeting three-dimensional genome architecture might be one of the mechanisms of CQ’s diverse therapeutic actions. Based on this hypothesis, new approaches to the treatment and prevention of cancer and coronavirus disease 2019 (COVID-19) are proposed.